Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [IFRS] (Consolidated)

Performance Overview

For the third quarter of the fiscal year ending March 2026, consolidated revenue was 2,737.3 billion yen (8.2% decrease YoY), core operating income was 185.6 billion yen (2.4% decrease YoY), and operating income was 113.3 billion yen (22.2% decrease YoY). Meanwhile, net income attributable to owners of the parent for the quarter was 105.4 billion yen, a 77.6% increase from the previous year. This increase includes gains on the sale of the non-continuing business, Tanabe Mitsubishi Pharma Corporation (currently Tanabe Pharma Corporation). By segment, Specialty Materials and Industrial Gas segments saw increased profits, while MMA & Derivatives and Basic Materials & Polymers segments experienced declines in both sales and profits.

Outlook and Business Structural Reforms

The full-year earnings forecast for the fiscal year ending March 2026 remains at revenue of 3,672.0 billion yen (7.0% decrease YoY) and core operating income of 250.0 billion yen (9.2% increase YoY), while downward revisions were made for operating income to 70.0 billion yen (60.2% decrease from previous forecast) and net income attributable to owners of the parent to 47.0 billion yen (62.4% decrease from previous forecast). The main reason is the anticipated additional extraordinary losses related to structural reforms following the withdrawal from the coke and carbon materials business. Production cessation is scheduled for the second half of FY2027, affecting approximately 600 employees. This aims to optimize the business portfolio in the mid- to long-term.